Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ArcherDX
MedTech
ArcherDX drops IPO plans in favor of a $1.4B takeover by Invitae
Personalized cancer test developer ArcherDX is walking away from plans to take itself public and into the arms of Invitae.
Conor Hale
Jun 23, 2020 10:30am
Personalized cancer test maker ArcherDX files $100M IPO
Jun 8, 2020 12:03pm
ArcherDX expands co-marketing, IVD partnerships with Illumina
Jan 12, 2020 9:56am
ArcherDX raises $60M for minimal residual disease diagnostics
May 15, 2019 10:02am
Celgene partner raises $35M to grow cancer test business
Mar 21, 2018 8:55am
ArcherDX, HeliTec partner on NGS cancer diagnostics in China
Apr 5, 2017 9:45am
